The Pediatric Infectious Disease Journal · 2016 · 38 citations · 5 references
Pediatric Leukemia PatientHealth SciencesAntibioticsAntimicrobial StewardshipPharmacologyMultidrug-resistant PseudomonasPediatric PatientsMultidrug-resistant Pseudomonas AeruginosaPharmacotherapyAntimicrobial TherapyAntimicrobial PharmacokineticsAntibacterial AgentAntimicrobial ChemotherapyAntimicrobial CompoundMedicineClinical MicrobiologyAntimicrobial ResistanceDrug Resistance
Multidrug-resistant Pseudomonas aeruginosa is of increasing concern in pediatric patients. Ceftolozane/tazobactam is a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant Pseudomonas; however, no data exist on its use in children. This report summarizes the treatment of a multidrug-resistant P. aeruginosa bloodstream infection in a pediatric leukemia patient with ceftolozane/tazobactam and provides the first description of its pharmacokinetics in pediatrics.
5
Alan Xiao, Benjamin Miller, Jennifer A. Huntington et al. · The Journal of Clinical Pharmacology · 2015 · 149 citations · Full text
Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia
Bendik Lund, Ann Åsberg, Mats Heyman et al. · Pediatric Blood & Cancer · 2010 · 126 citations
Samuel L Aitken, Jerry Altshuler, David J. Guervil et al. · International Journal of Antimicrobial Agents · 2015 · 68 citations
Antimicrobial Susceptibility, Clinical Failure, Respiratory Infection +7